In vitro–in vivo correlations for three different commercial immediate-release indapamide tablets

References

• US Department of Health and Human Services/Food and Drug Administration/Centre for Drug Evaluation and Research. Guidance for industry: dissolution testing of immediate release dosage forms. Rockville, MD; 1997
   Google Scholar
• Upppoor VRS. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release 2001;72:127–32
   PubMed Web of Science ®Google Scholar
• Sunkara G, Chilukuri DM. In vitro--in vivo correlation: an important tool in the development of drug delivery systems. Drug Dev Deliv 2003;3:(4)
   Google Scholar
• United State Pharmacopeial Convention: US Pharmacopeia 32-National Formulary 27, Rockville, MD, 1; 2009
   Google Scholar
• Gordon MS, Chowhan Z. In vivo--in vitro correlations for four differently dissolving Ketorolac tablets. Biopharm Drug Dispos 1996;17:481–92
   PubMed Web of Science ®Google Scholar
• Rossi RC, Dias CL, Bajerski L, et al. Development and validation of discriminating method of dissolution for fosamprenavir tablets based on in vivo data. J Pharm Biomed 2011;54:439–44
   PubMed Web of Science ®Google Scholar
• Lue BM, Nilsen FS, Magnussen T, et al. Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound. Eur J Pharm Biopharm 2008;69:648–57
   PubMed Web of Science ®Google Scholar
• Jantratid E, Maio VD, Ronda E, et al. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci 2009;37:434–41
   PubMed Web of Science ®Google Scholar
• Francisco GE, Honigberg IL, Stewart JT, et al. In vitro and in vivo bioequivalence of commercial prednisone tablets. Biopharm Drug Dispos 1984;5:335–44
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Sada N, Sugawara M, et al. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. Int J Pharmaceut 2001;221:87–94
   PubMed Web of Science ®Google Scholar
• He X, Sugawara M, Takekuma Y, Miyazaki K. Absorption of ester prodrugs in Caco-2 and rat intestine models. Antimicrob Agents Chemother 2004;48:2604–9
   PubMed Web of Science ®Google Scholar
• Li ZQ, He X, Gao X, et al. Study on dissolution and absorption of four dosage forms of Isosorbide mononitrate: level A in vitro–in vivo correlation. Eur J Pharm Biopharm 2011;79:364–71
   PubMed Web of Science ®Google Scholar
• Liu W, He X, Li Z, et al. Development of a bionic system for the simultaneous prediction of the release/absorption characteristics of enteric coated formulations. Pharm Res 2013;30:596--605
   Google Scholar
• Stetinova V, Kubant P, Svoboda Z, et al. In vitro and in vivo prediction of indapamide gastrointestinal absorption. Toxicol Lett 2007;172:S56
   Web of Science ®Google Scholar
• Grebow PE, Treitman JA. Pharmacokinetics of Indapamide in dogs. J Pharm Sci 1981;70:1310–12
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165–75
   PubMedGoogle Scholar
• Grebow PE, Treitman JA, Barry EP, et al. Pharmacokinetics and bioavailability of indapamide – a new antihypertensive drug. Eur J Clin Pharmacol 1982;22:295–9
   PubMed Web of Science ®Google Scholar
• Wang Y, Nedelman J. Bias in the Wagner–Nelson estimate of the fraction of drug absorbed. Pharm Res 2002;19:470–6
   PubMed Web of Science ®Google Scholar
• Gohel M, Delvadia RR, Parikh DC, et al. Simplified mathematical approach for back calculation in Wagner–Nelson method. Pharm Rev 2005;3. Available from: http://www.pharmainfo.net/reviews/simplified-mathematical-approach-back-calculation-wagner-nelson-method [last accessed 11 Jan 2013]
   Google Scholar
• Ramenskaya GV, Shlykov VS, Dekhanova OA. Comparative in vitro dissolution testing of indapamide prolonged-release tablets. Pharm Chem J 2008;42:726–9
   Google Scholar
• Goodman G. The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research. Guidance for industry; Extended release oral dosage forms: development, evolution and application of in vitro in vivo correlations. Rockville, MD; 1997
   Google Scholar
• Shohin IE, Ramenskaya GV, Savchenko AY. Developing in vitro–in vivo correlation (IVIVC) for trimetazidine, indapamide and ciprofloxacin extended-release solid oral dosage forms. Int Pharm BioSci 2011;2:573–80
   Google Scholar
• Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413–20
   PubMed Web of Science ®Google Scholar
• Dalton JT, Straughn AB, Dickason DA, Grandolfi GP. Predictive ability of level A in vivo--in vitro correlation for ringcap controlled-release acetaminophen tablets. Pharm Res 2001;18:1729–34
   PubMed Web of Science ®Google Scholar